Physician profile
Michael L Rosenberg
NPI 1275533440
$1,010.62
in general payments reported to CMS, 2019-2025
17 companies · $95.25 in 2025
The $95.25 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $11.74 · 2021: $45.12 · 2022: $328 · 2023: $272 · 2024: $123 · 2025: $95.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $490.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $207.72 | 2022-2025 | |
| Sk Life Science, INC. | $155.01 | 2021-2024 | |
| Celgene Corporation | $129.79 | 2022-2023 | Zeposia |
| Abbott Laboratories | $120.67 | 2019 | |
| Abbvie INC. | $85.37 | 2023-2025 | Botox |
| Teva Pharmaceuticals USA, INC. | $66.02 | 2020-2024 | Austedo Xr |
| Ucb, INC. | $56.69 | 2024 | Briviact |
| Lilly USA, LLC | $30.43 | 2022 | |
| Amgen INC. | $28.51 | 2022 | |
| Medtronic, INC. | $22.16 | 2022 | |
| Biogen, INC. | $20.89 | 2021 | |
| Argenx US, INC. | $16.69 | 2023 | Vyvgart Hytrulo |
| Collegium Pharmaceutical, INC. | $15.00 | 2022 | |
| Eisai INC. | $14.40 | 2022 | |
| Genentech USA, INC. | $14.25 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $13.79 | 2022 | |
| Impel Pharmaceuticals INC. | $13.23 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.